Obesity, physical activity and cardiovascular risk: ergoanthropometric classification, pharmacological variables, biomarkers and "obesity paradox";Obesidad, actividad física y riesgo cardiovascular: clasificación ergoantropométrica, variables farmacológicas, biomarcadores y «paradoja del obeso»

Medicina Clinica

Volumn 134, Issue 11, 2010, Pages 492-498

  Morales Salinas, Alberto ^a   Coca, Antonio ^b  

^a Servicio de Cardiologia   (Cuba)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; BRAIN NATRIURETIC PEPTIDE;

ANTHROPOMETRY; ARTICLE; CARDIOVASCULAR RISK; DISEASE MARKER; HEALTH SURVEY; HUMAN; HYPERTENSION; OBESITY; PHYSICAL ACTIVITY; PREVALENCE;

ANTHROPOMETRY; BODY WEIGHT; CARDIOVASCULAR DISEASES; HUMANS; MOTOR ACTIVITY; OBESITY; POLYPHARMACY; RISK FACTORS;

EID: 77951022605     PISSN: 00257753     EISSN: 15788989     Source Type: Journal    
DOI: 10.1016/j.medcli.2009.02.038     Document Type: Article

References (102)

1. World Health Organization. The world health report 2002-Reducing Risks, Promoting Healthy Life [citado 30 Jun 2008]. Disponible en: URL: http://www.who.int/whr/2002/en/.
2. Caballero B. The global epidemic of obesity: An overview. Epidemiol Rev 29 (2007) 1-5
3. o 311. Geneva, Switzerland: World Health Organization; 2006. [citado 30 Jun 2008]. Disponible en: URL: www.who.int/mediacentre/factsheets/fs311/en/print.html/.
4. Burt V.L., Whelton P., Roccella E.J., Brown C., Cutler J.A., Higgins M., et al. Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension 25 (1995) 305-313
5. Mokdad A.H., Serdula M.K., Dietz W.H., Bowman B.A., Marks J.S., and Soplan J.P. The spread of the obesity epidemic in the United States, 1991-1998. JAMA 282 (1999) 1519-1522
6. Ogden C.L., Carroll M.D., Curtin L.R., McDowell M.A., Tabak C.J., and Flegal K.M. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA 295 (2006) 1549-1555
7. Medrano M.J., Pastor-Barriuso R., Boix R., Barrio J.L., Damián J., Álvarez R., et al. Riesgo coronario atribuible a los factores de riesgo cardiovascular en población española. Rev Esp Cardiol 60 (2007) 1250-1256
8. Cea-Calvo L., Moreno B., Monereo S., Gil-Guillén V., Lozano J.V., Martí-Canales J.C., et al. Prevalencia de sobrepeso y obesidad en población española de 60 años o más y factores relacionados. Estudio PREV-ICTUS. Med Clin (Barc) 131 (2008) 205-210
9. Poirier P., Giles T.D., Bray G.A., Hong Y., Stern J.S., Pi-Sunyer F.X., et al. Obesity and cardiovascular disease: Pathophysiology, evaluation, and effect of weight loss: An update of the 1997 American Heart Association scientific statement on obesity and heart disease from the Obesity Committee of the Council on nutrition, physical activity, and metabolism. Circulation 113 (2006) 898-918
10. Iacobellis G., Ribaudo M.C., Zappaterreno A., Iannucci C.V., and Leonetti F. Prevalence of uncomplicated obesity in an italian obese population. Obes Res 13 (2005) 1116-1122
11. Karelis A.D., Brochu M., and Rabasa-Lhoret R. Can we identify metabolically healthy but obese individuals (MHO)?. Diabetes Metab 30 (2004) 569-572
12. Haslam D.W., and James W.P. Obesity. Lancet 366 (2005) 1197-1209
13. Flegal K.M., Graubard B.I., Williamson D.F., and Gail M.H. Excess deaths associated with underweight, overweight, and obesity. JAMA 293 (2005) 1861-1867
14. Peeters A., Barendregt J.J., Willekens F., Mackenbach J.P., Al Mamun A., Bonneux L., NEDCOM, and the Netherlands Epidemiology and Demography Compression of Morbidity Research Group. Obesity in adulthood and its consequences for life expectancy: A life-table analysis. Ann Intern Med 138 (2003) 24-32
15. Banegas J.R., López E., Gutiérrez J.L., Guallar P., and Rodríguez-Artalejo F. A simple estimate of mortality attributable to excess weight in the European Union. Eur J Clin Nutr 57 (2003) 201-208
16. Banegas J.R., Villar F., and Rodríguez-Artalejo F. Riesgo atribuible a los principlaes factores de riesgo en la población española. In: Marrugat J., and Fernández E. (Eds). Monitorización epidemiológica de las enfermedades cardiovasculares en España y estrategias preventivas (2005), Graficas Enar, SA, Madrid 86
17. Weight-control Information Network. Statistics related to overweight and obesity [citado 30 Jun 2008]. Disponible en: URL: http://www.win.niddk.nih.gov/statistics/index.htm.
18. Rosamond W., Flegal K., Friday G., Furie K., Go A., Greenlund K., et al. Heart disease and stroke statistics-2007 update: A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 115 (2007) 69-171
19. Kim S., and Popkin B.M. Commentary: Understanding the epidemiology of overweight and obesity a real global public health concern. Int J Epidemiol 35 (2006) 60-67
20. Drain A.J., Gerrard C., Ferguson J.I., Cafferty F., Gurprashad R., and Vuylsteke A. Does body mass index (BMI) affect cost in cardiac surgery? 'A pound for pound analysis'. Interact Cardiovasc Thorac Surg 5 (2006) 282-284
21. Williamson D.F., Thompson T.J., Thun M., Flanders D., Pamuk E., and Byers T. Intentional weight loss and mortality among overweight individuals with diabetes. Diabetes Care 23 (2000) 1499-1504
22. Grundy S.M. Obesity, metabolic syndrome, and cardiovascular disease. J Clin Endocrinol Metab 89 (2004) 2595-2600
23. Musaad S., and Haynes E.N. Biomarkers of obesity and subsequent cardiovascular events. Epidemiol Rev 29 (2007) 98-114
24. Graham I., Atar D., Borch-Johnsen K., Boysen G., Burell G., Cifkova R., et al. Fourth joint task force of European and other societies on cardiovascular disease prevention in clinical practice. Eur J Cardiovasc Prev Rehabil 14 (2007) E1-E40
25. Rexrode K.M., Buring J.E., and Manson J.E. Abdominal and total adiposity and risk of coronary heart disease in men. Int J Obes Relat Metab Disord 25 (2001) 1047-1056
26. Alegría Ezquerra E., Castellano Vázquez J.M., and Alegría Barrero A. Obesidad, síndrome metabólico y diabetes: implicaciones cardiovasculares y actuación terapéutica. Rev Esp Cardiol 61 (2008) 752-764
27. Rubio M.A., Salas-Salvadó J., Barbany M., Moreno B., Aranceta J., Bellido D., et al. Consenso SEEDO 2007 para la evaluación del sobrepeso y la obesidad y el establecimiento de criterios de intervención terapéutica. Rev Esp Obes 12 (2007) 7-48
28. Aranceta J., Foz M., Gil B., Jover E., Mantilla T., Millán J., et al. Documento de consenso: obesidad y riesgo cardiovascular. Clin Invest Arterioscl 15 (2003) 196-233
29. Keys A., Fidanza F., Karvonen M.J., Kimura N., and Taylor H.L. Indices of relative weight and obesity. J Chron Dis 25 (1972) 329-343
30. Lee J., Kolonel L.N., and Hinds M.W. The use of an inappropriate weight-height derived index of obesity can produce misleading results. Int J Obes 6 (1982) 233-239
31. Garrow J.S. Indices of adiposity. Nutr Abstr Rev 38 (1983) 697-708
32. Silventoinen K., Zdravkovic S., Skytthe A., McCarron P., Herskind A.M., Koskenvuo M., et al. Association between height and coronary heart disease mortality: A prospective study of 35,000 twin pairs. Am J Epidemiol 163 (2006) 615-621
33. Welborn T.A., Knuiman M.W., and Vu H. Body mass index and alternative indices of obesity in relation to height, triceps skinfold and subsequent mortality: The Busselton health study. Int J Obes Relat Metab Disord 24 (2000) 108-115
34. Yusuf S., Hawken S., Ounpuu S., Bautista L., Franzosi M.G., Commerford P., et al. Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: A case-control study. Lancet 366 (2005) 1640-1649
35. Li T.Y., Rana J.S., Manson J.E., Manson J.E., Willet W.C., Stampfer M.J., et al. Obesity as compared with physical activity in predicting risk of coronary heart disease in women. Circulation 113 (2006) 499-506
36. Onat A., Avci G.S., Barlan M.M., Uyarel H., Uzunlar B., and Sansoy V. Measures of abdominal obesity assessed for visceral adiposity and relation to coronary risk. Int J Obes Relat Metab Disord 28 (2004) 1018-1025
37. Vázquez G., Duval S., Jacobs D.R., and Silventoinen K. Comparison of body mass index, waist circumference, and waist/hip ratio in predicting incident diabetes: A meta-analysis. Epidemiol Rev 29 (2007) 115-128
38. Aranceta J., Pérez Rodrigo C., Serra Majem L.I., Vioque J., Tur Marí J.A., Mataix Verdú J., et al. Estudio DORICA: dislipemia, obesidad y riesgo cardiovascular. In: Aranceta J., Foz M., Gil B., Jover E., Mantilla T., and Millán J. (Eds). Obesidad y riesgo cardiovascular. Estudio DORICA (2004), Editorial Médica Panamericana, Madrid 125-156
39. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: The evidence report [citado 30 Jun 2008]. Disponible en: URL: http://www.nhlbi.nih.gov/guidelines/obesity/ob_gdlns.htm.
40. Kannel W.B., LeBauer E.J., Dawber T.R., and McNamara P.M. Relation of body weight to development of coronary heart disease: The Framingham Study. Circulation 35 (1967) 734-744
41. Eckel R.H., and Krauss R.M. American Heart Association call to action: Obesity as a major risk factor for coronary heart disease. Circulation 97 (1998) 2099-2100
42. Morales Salinas A., Marrugat J., and Coca A. Limitaciones de la valoración clínica de obesidad: reflexiones a propósito de la declaración de la American Heart Association de 2006. Rev Esp Cardiol 60 (2007) 992-993
43. Engeland A., Bjorge T., Sogaard A.J., and Tverdal A. Body mass index in adolescence in relation to total mortality: 32-year follow-up of 227,000 Norwegian boys and girls. Am J Epidemiol 157 (2003) 517-523
44. Yusuf S., Hawken S., Ounpuu S., Dans T., Avezum A., Lanas F., et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (The INTERHEART Study): Case control study. Lancet 364 (2004) 937-952
45. Weinstein A.R., Sesso H.D., Lee I.M., Rexrode K.M., Cook N.R., Manson J.E., et al. The joint effects of physical activity and body mass index on coronary heart disease risk in women. Arch Intern Med 168 (2008) 884-890
46. Franco O.H., De Laet C., Peeters A., Jonker J., Mackenbach J., and Nusselder W. Effects of physical activity on life expectancy with cardiovascular disease. Arch Intern Med 165 (2005) 2355-2360
47. Gang G., Tuomilehto J., Silventoinen K., Barengo N., and Jousilahti P. Joint effects of physical activity, body mass index, waist circumference and waist-to-hip ratio with the risk of cardiovascular disease among middle-aged Finnish men and women. Eur Heart J 25 (2004) 2212-2219
48. Stevens J., Cai J., Evenson K.R., and Thomas R. Clinics study fitness and fatness as predictors of mortality from all causes and from cardiovascular disease in men and women in the lipid research. Am J Epidemiol 156 (2002) 832-841
49. Pitsavos C., Kavouras S.A., Panagiotakos D.B., Arapi S., Anastasiou C.A., Zombolos S., et al. Physical activity status and acute coronary syndromes survival the GREECS (Greek Study of Acute Coronary Syndromes) study. J Am Coll Cardiol 51 (2008) 2034-2039
50. Boraita Pérez A. Ejercicio, piedra angular de la prevención cardiovascular. Rev Esp Cardiol 61 (2008) 514-528
51. Calle E.E., Thun M.J., Petrelli J.M., Rodríguez C., and Heath C.W. Body-mass index and mortality in a prospective cohort of U.S. adults. N Engl J Med 341 (1999) 1097-1105
52. Horwich T.B., Fonarow G.C., Hamilton M.A., MacLellan W.R., Woo M.A., and Tillisch J.H. The relationship between obesity and mortality in patients with heart failure. J Am Coll Cardiol 38 (2001) 789-795
53. Davos C.H., Doehner W., Rauchhaus M., Cicoira M., Francis D.P., Coats A.J., et al. Body mass and survival in patients with chronic heart failure without cachexia: The importance of obesity. J Card Fail 9 (2003) 29-35
54. Mosterd A., Cost B., Hoes A.W., De Bruijne M.C., Deckers J.W., Hofman A., et al. The prognosis of heart failure in the general population: The Rotterdam study. Eur Heart J 22 (2001) 1318-1327
55. Lissin L.W., Gauri A.J., Froelicher V.F., Ghayoumi A., Myers J., and Giacommini J. The prognostic value of body mass index and standard exercise testing in male veterans with congestive heart failure. J Card Fail 8 (2002) 206-215
56. Kragelund C., Hassager C., Hildebrandt P., Torp-Pedersen C., and Kober L. Impact of obesity on long-term prognosis following acute myocardial infarction. Int J Cardiol 98 (2005) 123-131
57. Bozkurt B., Deswal A., and Housten T.X. Obesity as a prognostic factor in chronic symptomatic heart failure. Am Heart J 150 (2005) 1233-1239
58. Cicoria M., Maggioni A.P., Latini R., Barlera S., Carreta E., Janosi A., et al. Body mass index, prognosis and mode of death in chronic heart failure: Results from the Valsartan Heart Failure Trial. Eur J Heart Fail 9 (2007) 397-402
59. Kalantar-Zadeh K., Block G., Horwich T., and Fonarow G.C. Reverse epidemiology of conventional cardiovascular risk factors in patients with chronic heart failure. J Am Coll Cardiol 43 (2004) 1439-1444
60. Elosua R., Vega G., Rohlf I., Aldasorod E., Navarro C., Cabades A., et al. Smoking and myocardial infarction case-fatality: Hospital and population approach. Eur J Cardiovasc Prev Rehabil 14 (2007) 561-567
61. Fonarow G.C., Srikanthan P., Costanzo M.R., Cintron G.B., Lopatin M., and ADHERE Scientific Advisory Committee and Investigators. An obesity paradox in acute heart failure: Analysis of body mass index and inhospital mortality for 108927 patients in the Acute Decompensated Heart Failure National registry. Am Heart J 153 (2007) 74-81
62. Sagar U.S., Ahmed M.M., Adams S., and Whellan D.J. Does body mass index really matter in the management of heart failure?. Cardiol Rev 16 (2008) 124-128
63. Zamora E., Lupón J., Urrutia A., González B., Mas D., and Pascual T. ¿El índice de masa corporal influye en la mortalidad de los pacientes con insuficiencia cardíaca?. Rev Esp Cardiol 60 (2007) 1027-1034
64. Artham S.M., and Ventura H.O. Insuficiencia cardíaca y la «paradoja de la obesidad»: la historia continúa. Rev Esp Cardiol 60 (2007) 1013-1017
65. Morales Salinas A. Paradoja de la obesidad y susceptibilidad del bajo peso. Rev Esp Cardiol 61 (2008) 653
66. Zamora E., and Lupón J. Respuesta. Rev Esp Cardiol 61 (2008) 654
67. Artham S.M., and Ventura H.O. Respuesta. Rev Esp Cardiol 61 (2008) 654-656
68. Gustafsson F, Kragelund CB, Torp-Pedersen C, Seibaek M, Burchardt H, Akkan D, et al and DIAMOND study group. Effect of obesity and being overweight on long-term mortality in congestive heart failure: Influence of left ventricular systolic function. Eur Heart J. 2005;26:58-64.
69. Curtis J.P., Selter J.G., Wang Y., Rathore S.S., Jovin I.S., Jadbabaie F., et al. The obesity paradox: Body mass index and outcomes in patients with heart failure. Arch Intern Med 165 (2005) 55-61
70. Oreopoulos A., Padwal R., Kalantar-Zadeh K., Fonarow G.C., Norris C.M., and McAlister F.A. Body mass index and mortality in heart failure: A meta-analysis. Am Heart J 156 (2008) 13-22
71. Fonarow G.C., Adams K., Abraham W.T., Nancy C.W., Boscardin J., ADHERE Scientific Advisory Committee, Study Group, and and Investigators. Risk stratification for in-hospital mortality in acutely decompensated heart failure. JAMA 293 (2005) 572-580
72. Granger C.B., Goldberg R.J., Dabbous O., Pieper K.S., Tagle K.A., Cannon C.P., et al. Predictors of hospital mortality in the global registry of acute coronary events. Arch Intern Med 163 (2003) 2345-2353
73. Morrow D.A., Antman E.M., Charlesworth A., Cairns R., Murphy S.A., Lemos J.A., et al. TIMI risk score for ST-elevation myocardial infarction: A convenient, bedside, clinical score for risk assessment at presentation: An intravenous nPA for treatment of infarcting myocardium early II trial substudy. Circulation 102 (2000) 2031-2037
74. Sanz G.A. Estratificación del riesgo en los síndromes coronarios agudos: un problema no resuelto. Rev Esp Cardiol 60 Supl 3 (2007) 23-30
75. Khan S.Q., Quinn P., Davies J.E., and Ng L.L. N-terminal pro-B-type natriuretic peptide is better than TIMI risk score at predicting death after acute myocardial infarction. Heart 94 (2008) 40-43
76. Zethelius B., Berglund L., Sundström J., Ingelsson E., Basu S., Larsson A., et al. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med 358 (2008) 2107-2116
77. Kragelund C., Grønning B., Køber L., Hildebrandt P., and Steffensen R. N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. N Engl J Med 352 (2005) 666-675
78. Peacock W.F., De Marco T., Fonarow G.C., Diercks D., Wynne J., Apple F.S., et al. Cardiac troponin and outcome in acute heart failure. N Engl J Med 358 (2008) 2117-2126
79. Shlipak M.G., Sarnak M.J., Katz R., Fried L.F., Seliger S.L., Newman A.B., et al. Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med 352 (2005) 2049-2060
80. Bogaty P., Boyer L., Simard S., Dauwe F., Dupuis R., Verret B., et al. Clinical utility of C-reactive protein measured at admission, hospital discharge, and 1 month later to predict outcome in patients with acute coronary disease: The RISCA (Recurrence and Inflammation in the Acute Coronary Syndromes) study. J Am Coll Cardiol 51 (2008) 2339-2346
81. Bayes-Genis A., Lloyd-Jones D.M., Van Kimmenade R.R., Lainchbury J.G., Richards A.M., Ordoñez-Llanos J., et al. Effect of body mass index on diagnostic and prognostic usefulness of amino-terminal pro-train natriuretic peptide in patients with acute dyspnea. Arch Intern Med 167 (2007) 400-407
82. Heidenreich P.A., and McClellan M. Trends in treatment and outcomes for acute myocardial infarction: 1975-1995. Am J Med 110 (2001) 165-174
83. Swedberg K., Cleland J., Dargie H., Drexler H., Follath F., Komajda M., et al. Task force for the diagnosis treatment of chronic heart failure of the European Society of Cardiology. [Guidelines for the Diagnosis and Treatment of Chronic Heart Failure: Executive summary (update 2005)]. Eur Heart J 26 (2005) 1115-1140
84. Picote D.M., Titler M.G., Dochterman J., Shever L., Kim T., Abramowitz P., et al. Predictors of medication errors among elderly hospitalized patients. Am J Med Qual 23 (2008) 115-127
85. Lazarou J., Pomeranz B.H., and Corey P.N. Incidence of adverse drug reactions in hospitalized patients: A meta-analysis of prospective studies. JAMA 279 (1998) 1200-1205
86. Jochmann N., Stangl K., Garbe E., Baumann G., and Stangl V. Female-specific aspects in the pharmacotherapy of chronic cardiovascular diseases. Eur Heart J 26 (2005) 1585-1595
87. Morales Salinas A., López G., and Ramos R. Letter to Editor. Am Heart J 155 (2008) e1
88. Curtis J.P., Alexander J.H., Huang Y., Wallentin L., Verheugt F., Armstrong P.W., et al. Efficacy and safety of two unfractionated heparin dosing strategies with tenecteplase in acute myocardial infarction (results from assessment of the safety and efficacy of a new thrombolytic regimens 2 and 3). Am J Cardiol 94 (2004) 279-283
89. Rathore S., Curtis J., Wang Y., Bristol M., and Krumholz H. Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA 289 (2003) 871-878
90. Adams K.F., Patterson J.H., Gattis W.A., O'Connor C.M., Lee C.R., Schwartz T.A., et al. Relationship of serum digoxin concentration to mortality and morbidity in women in the digitalis investigation group trial. J Am Coll Cardiol 46 (2005) 497-504
91. Donnelly R. Characterizing variability in cardiovascular drug responses. Br J Clin Pharmacol 57 (2004) 535-537
92. Rydén L., Armstrong P.W., Cleland J.G.F., Horowitz J.D., Massie B.M., Packer M., et al. Efficacy and safety of high-dose lisinopril in chronic heart failure patients at high cardiovascular risk, including those with diabetes mellitus. Results from the ATLAS trial. Eur Heart J 21 (2000) 1967-1978
93. Nieminen M.S., Böhm M., Cowie M.R., Drexler H., Filippatos G.S., and Jondeau G. Guías de práctica clínica sobre el diagnóstico y tratamiento de la insuficiencia cardíaca aguda. Rev Esp Cardiol 58 (2005) 389-429
94. Sagar U.S., Ahmed M.M., Adams S., and Whellan D.J. Does body mass index really matter in the management of heart failure?. Cardiol Rev 16 (2008) 124-128
95. Abdulla J., Køber L., Abildstrøm S.Z., Christensen E., James F.P.T., and Torp-Pedersen C. Impact of obesity as a mortality predictor in high-risk patients with myocardial infarction or chronic heart failure: A pooled analysis of five registries. Eur Heart J 29 (2008) 594-601
96. Lavie C.J., Osman A.F., Milani R.V., and Mehra M.R. Body composition and prognosis in chronic systolic heart failure: The obesity paradox. Am J Cardiol 91 (2003) 891-894
97. Anker S.D., Ponikowski P., Varney S., Chua T.P., Clark A.L., Webb-Peploe K.M., et al. Wasting as independent risk factor for mortality in chronic heart failure. Lancet 349 (1997) 1050-1053
98. Reeves B.C., Ascione R., Chamberlain M.H., and Angelini G.D. Effect of body mass index on early outcomes in patients undergoing coronary artery bypass surgery. J Am Coll Cardiol 42 (2003) 668-676
99. Potapov E.V., Loebe M., Anker S., Stein J., Bondy S., Nasseri B.A., et al. Impact of body mass index on outcome in patients after coronary artery bypass grafting with and without valve surgery. Eur Heart J 24 (2003) 1933-1941
100. Thomas R., and Wilson M.M.G. Cachexia: Pathophysiology and clinical relevance. Am J Clin Nutr 83 (2006) 735-743
101. Kenchaiah S., Pocock S.J., Wang D., Finn P.V., Zornoff L.A.M., Skali H., et al. Body mass index and prognosis in patients UIT chronic heart failure insights from the candesartan in heart failure: Assessment of reduction in mortality and morbidity (CHARM) program. Circulation 116 (2007) 627-636
102. Do Lee C., Blair S.N., and Jackson A.S. Cardiorespiratory fitness, body composition, and all-cause and cardiovascular disease mortality in men. Am J Clin Nutr 69 (1999) 373-380